The first-quarter earnings season for the Medical sector will be in full swing this week as several drugmakers are slated to ...

Amgen’s product sales are expected to have been driven by strong volume growth of products like Evenity, Repatha, Kyprolis ...

On average, BPMC delivered an earnings surprise of 13.10% in the last four quarters. Denali Therapeutics DNLI has an Earnings ESP of +4.87% and a Zacks Rank #3. Denali’s stock has risen 20.2% ...

Viatris VTRS, a global healthcare company, is scheduled to report first-quarter 2025 results on May 8, 2025. The Zacks ...

On the o Denali Therapeutics (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into ...

Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's ...

Viatris VTRS, a global healthcare company, is scheduled to report first-quarter 2025 results on May 8, 2025. The Zacks Consensus Estimate for revenues is pegged at $3.24 billion, while the same ...